Litcius/Paper detail

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun Ju Lee, Ranjana J Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell

2020The Lancet Haematology97 citationsDOI

Topics & Concepts

MedicineBrentuximab vedotinDacarbazineInternal medicineABVDNivolumabVinblastineOncologyChemotherapy regimenChemotherapyBleomycinLymphomaSurgeryCancerVincristineHodgkin lymphomaCyclophosphamideImmunotherapyLymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCutaneous lymphoproliferative disorders research
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial | Litcius